Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Oral SHR2150 in Healthy Subjects
NCT04802811Phase 1Completed
- Sponsor
- Hengrui
- Start
- Mar 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR2150 in human immunodeficiency virus type 1 infection (HIV-1) (5 arms), sponsored by Hengrui. Primary endpoint: Incidence and severity of treatment-related adverse events at 9 days. Started Mar 2021; status: completed.
02
Drugs
SHR2150
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04802811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802811.